Molecular Cytogenetics Market Size

Molecular Cytogenetics Market Analysis

The molecular cytogenetics market is expected to register a CAGR of 7.5% over the forecast period.

COVID-19 had a significant impact on the molecular cytogenetics market. During the pandemic, the alternation in genetic materials in affected persons was identified through the help of cytogenetics. For instance, as per the article published in July 2021 in Nature journal, genetic factors influencing COVID-19 susceptibility and severity offered new biological insights into disease etiology and identify molecular targets for therapeutic development or medication repurposing. In the current situation, as the restrictions are lifted the market is expected to witness growth in the coming years due to the rise in utilization of cytogenetic research studies and the increase in the genetic disease population.

The growing prevalence of cancer and genetic disorders directly impacts the increased demand for the molecular cytogenetic market. For instance, as per the American Cancer Society, 1.9 million people are estimated to be diagnosed with cancer in the United States in 2022. Cancer cytogenetics not only gives important information to help with the treatment of cancer patients but also serves as a guide to finding the genes that cause these neoplastic states, which has stimulated the development of molecularly targeted therapies in the area of personalized medicine. Thus, the rise in cancer cases is anticipated to increase market growth over the forecast period.

Furthermore, the genetic data accumulated each day are closely associated with the diagnosis and prognosis of neoplasm, thus widening the scope of cancer cytogenetics in various practices. Molecular cytogenetics has numerous applications in a number of genetic diseases such as Down syndrome, Edwards' syndrome, Patau syndrome, and Turner syndrome. For instance, as per the article published in March 2022 in Molecular Cytogenetics journal, the researchers reported a rare mosaic X-ring chromosome in a patient with Turner syndrome that had highly variable phenotypes through the cytogenetic microarray experiment. The researchers identified the phenotype in terms of clinical symptoms, ultrasound diagnosis, and cytogenetics, of the patient with a rare genotype and Turner syndrome. Thus, such studies utilizing the application of cytogenetics are expected to drive market growth over the forecast period. Similarly, as per the article published in July 2022 in PubMed, the researchers strongly emphasized the importance of cytogenetic study complemented with molecular cytogenetic study and karyotype-phenotype correlations in patients with Turner Syndrome to obtain information regarding the genotype-phenotype correlations related to the X chromosome. Thus, with the increase in the utilization of molecular cytogenetics in identifying the phenotypes in different genetic diseases, the demand for molecular cytogenetics is expected to register a significant rise in the forecast years.

Furthermore, technological advancements in the field of molecular cytogenetics are expected to drive market growth over the forecast period. For instance, in October 2022, Thermo Fisher Scientific upgraded its Applied Biosystems Chromosome Analysis Suite (ChAS) software through a collaboration with Genoox, a community-driven genomic data company. ChAS users will be able to access Genoox's cloud-based AI platform, Franklin, with the launch of CytoScan Automated Interpretation and Reporting (AIR) solution, making cytogenetic research data analysis easier.

Hence, due to the rise in cancer and genetic disease, and the increase in studies associated with molecular cytogenetics, the studied market is anticipated to witness growth over the forecast period. However, the high cost of treatment and lack of awareness about the emerging diagnostic technologies in cytogenetics are likely to restrain the market growth over the study period.